Summit Securities Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$120K Sell
130
-1,049
-89% -$1.06M 0.01% 270
2025
Q4
$1.27M Sell
1,179
-191
-14% -$183K 0.17% 102
2025
Q3
$1.05M Buy
1,370
+841
+159% +$626K 0.22% 102
2025
Q2
$412K Buy
+529
New +$411K 0.08% 157
2023
Q3
Sell
-1,030
Closed -$483K 824
2023
Q2
$483K Sell
1,030
-517
-33% -$217K 0.06% 146
2023
Q1
$531K Sell
1,547
-69
-4% -$23.3K 0.04% 137
2022
Q4
$591K Sell
1,616
-3,447
-68% -$1.22M 0.02% 217
2022
Q3
$1.64M Buy
5,063
+3,415
+207% +$1.08M 0.12% 112
2022
Q2
$534K Buy
1,648
+1,323
+407% +$397K 0.07% 184
2022
Q1
$93K Sell
325
-6,258
-95% -$1.61M 0.01% 521
2021
Q4
$1.82M Sell
6,583
-7,121
-52% -$1.81M 0.09% 171
2021
Q3
$3.17M Buy
13,704
+10,110
+281% +$2.5M 0.25% 97
2021
Q2
$825K Buy
+3,594
New +$722K 0.07% 287
2020
Q4
Sell
-15,400
Closed -$2.3M 584
2020
Q3
$2.28M Buy
15,400
+12,695
+469% +$1.96M 0.24% 87
2020
Q2
$444K Buy
2,705
+105
+4% +$16.1K 0.06% 251
2020
Q1
$361K Buy
+2,600
New +$357K 0.06% 183
2019
Q1
Sell
-7,900
Closed -$961K 293
2018
Q4
$914K Buy
+7,900
New +$882K 0.08% 147
2018
Q1
Sell
-3,800
Closed -$321K 202
2017
Q4
$321K Sell
3,800
-1,500
-28% -$128K 0.04% 123
2017
Q3
$453K Buy
+5,300
New +$435K 0.08% 115
2015
Q4
Sell
-600
Closed -$50K 377
2015
Q3
$50K Sell
600
-282
-32% -$23.8K 0.04% 164
2015
Q2
$74K Buy
+882
New +$67.2K 0.04% 154
2015
Q1
Sell
-2,500
Closed -$172K 533
2014
Q4
$172K Sell
2,500
-900
-26% -$60.7K 0.05% 210
2014
Q3
$220K Buy
3,400
+2,100
+162% +$133K 0.06% 203
2014
Q2
$81K Hold
1,300
0.03% 256
2014
Q1
$77K Sell
1,300
-3,400
-72% -$190K 0.05% 156
2013
Q4
$240K Buy
4,700
+1,200
+34% +$60.1K 0.04% 159
2013
Q3
$176K Buy
3,500
+3,200
+1,067% +$168K 0.06% 122
2013
Q2
$15K Buy
+300
New +$16.3K 0.01% 273

Other funds holding LLY

Summit Securities Group's LLY Position: Q1 2026 in Review

Summit Securities Group reduced its Eli Lilly (LLY) stake by 89% in Q1 2026, selling an estimated $1.06M and leaving 130 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #270.

Summit Securities Group first reported a position in LLY in Q2 2013 and has held it in 28 quarters since. The position peaked at $3.17M in Q3 2021. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Summit Securities Group held 130 shares of Eli Lilly worth $120K as of Q1 2026.
  • Summit Securities Group sold 1,049 Eli Lilly shares in Q1 2026, an estimated $1.06M.
  • Eli Lilly made up 0.01% of Summit Securities Group's portfolio in Q1 2026, its #270 holding.
  • Summit Securities Group first reported a position in Eli Lilly in Q2 2013 and has held it in 28 quarters since.
  • Summit Securities Group's Eli Lilly position peaked at $3.17M in Q3 2021.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.